Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2017 | Pages:
193 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline landscape. H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by a contagious virus. H1N1 flu infects the breathing tubes in nose, throat, and lungs. The disease is contagious. When people who have it cough or sneeze, they spray tiny drops of the virus into the air. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache and fatigue. Treatment includes medication (antiviral drugs). Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H1N1 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H1N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 6, 8, 7, 1, 41 and 6 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 11 and 3 molecules, respectively. Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H1N1 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H1N1 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H1N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Influenza A Virus, H1N1 Subtype Infections - Overview 9 Influenza A Virus, H1N1 Subtype Infections - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 15 Products under Development by Companies 17 Products under Development by Universities/Institutes 22 Influenza A Virus, H1N1 Subtype Infections - Therapeutics Assessment 23 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Influenza A Virus, H1N1 Subtype Infections - Companies Involved in Therapeutics Development 31 AbbVie Inc 31 Akshaya Bio Inc 31 Altimmune Inc 32 Antigen Express Inc 32 Beijing Minhai Biotechnology Co Ltd 33 CEL-SCI Corp 33 Cilian AG 34 Cocrystal Pharma Inc 34 ContraFect Corp 35 Curevac AG 35 EpiVax Inc 36 Etubics Corp 36 Gemmus Pharma Inc 37 Genentech Inc 37 iBio Inc 38 ILiAD Biotechnologies LLC 38 Inovio Pharmaceuticals Inc 39 Johnson & Johnson 39 Kineta Inc 40 Kyowa Hakko Kirin Co Ltd 40 Lakewood-Amedex Inc 41 Medicago Inc 41 MedImmune LLC 42 Microbiotix Inc 42 Mucosis BV 43 NanoViricides Inc 43 NewLink Genetics Corp 44 Novavax Inc 44 OPKO Health Inc 45 PeptiDream Inc 45 Prommune Inc 46 Protein Sciences Corp 46 Recce Ltd 47 Sanofi Pasteur SA 47 Sarepta Therapeutics Inc 48 SK Chemicals Co Ltd 48 Takeda Pharmaceutical Company Ltd 49 TechnoVax Inc 49 Touchlight Genetics Ltd 50 Vaccibody AS 50 Vaxart Inc 51 Vironova AB 51 Visterra Inc 51 Zydus Cadila Healthcare Ltd 52 Influenza A Virus, H1N1 Subtype Infections - Drug Profiles 53 AE-AI vaccine - Drug Profile 53 AEA-35p - Drug Profile 54 Antisense RNAi Oligonucleotides to Inhibit Matriptase for Influenza A Virus, H1N1 Subtype Infections - Drug Profile 55 Aspidasept - Drug Profile 56 AV-5027 - Drug Profile 57 AV-5080 - Drug Profile 58 CC-42344 - Drug Profile 59 cetylpyridinium chloride - Drug Profile 60 CF-401 - Drug Profile 61 CHOS-05 - Drug Profile 62 CiFlu - Drug Profile 63 diridavumab - Drug Profile 65 EP-67 - Drug Profile 67 ETBX-051 - Drug Profile 68 Flu-v - Drug Profile 69 Fluad (quadrivalent) - Drug Profile 71 Fludase - Drug Profile 72 FluGEM - Drug Profile 75 Gamma-Flu - Drug Profile 76 GP-1001 - Drug Profile 77 GP-1681 - Drug Profile 78 GREFLU/CAL - Drug Profile 80 H1N1 [A/Aichi/2/68] vaccine - Drug Profile 81 HB-36.6 - Drug Profile 82 IN-1 - Drug Profile 83 infectious disease vaccine - Drug Profile 84 Influ-nRNA - Drug Profile 85 influenza [strain A/H1N1] vaccine - Drug Profile 86 influenza [strain A/H1N1] vaccine - Drug Profile 88 influenza [strain A/H1N1] vaccine - Drug Profile 89 influenza [strain H1N1] (virus like particle) vaccine - Drug Profile 90 influenza [strain H1N1] vaccine - Drug Profile 91 influenza [strain H1N1] vaccine - Drug Profile 92 influenza [strain H1N1] vaccine - Drug Profile 93 influenza [strain H1N1] vaccine - Drug Profile 94 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 95 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 96 influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile 97 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile 98 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile 99 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile 102 influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile 103 influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile 104 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile 105 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 109 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 110 influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile 111 influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile 112 influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile 113 influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 114 influenza vaccine - Drug Profile 115 INO-3510 - Drug Profile 116 JNJ-3872 - Drug Profile 118 KIN-1148 - Drug Profile 121 KIN-1400 - Drug Profile 123 LEAPS-H1N1-DC - Drug Profile 125 MBX-2329 - Drug Profile 126 MBX-2546 - Drug Profile 127 Monoclonal Antibody to Inhibit Hemagglutinin for Influenza Virus A Infections - Drug Profile 128 Nasovax - Drug Profile 129 NBP-607 - Drug Profile 131 NEO-8877 - Drug Profile 132 Nucleozin - Drug Profile 133 NVINF-1 - Drug Profile 134 NVINF-2 - Drug Profile 139 Oligonucleotide to Activate RIG-1 for Influenza A Virus H1N1 Infections - Drug Profile 142 PD-001 - Drug Profile 143 Peptides for Influenza Infections - Drug Profile 144 pertussis [strain BPZE1] vaccine - Drug Profile 145 PNSIA-28 - Drug Profile 147 PNSIA-49 - Drug Profile 148 radavirsen - Drug Profile 149 RECCE-327 - Drug Profile 151 RNAi Oligonucleotides to Inhibit Matriptase for H1N1 Infection - Drug Profile 153 Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile 154 Small Molecules for RSV and Influenza A Infections - Drug Profile 155 Small Molecules to Block M2 Channel for Influenza Infections - Drug Profile 156 Small Molecules to Inhibit Influenza A Endonuclease for H1N1 Infections - Drug Profile 157 Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 158 TVX-002 - Drug Profile 159 VH-244 - Drug Profile 160 VIS-410 - Drug Profile 161 VNFC-045 - Drug Profile 164 VNFC-051 - Drug Profile 165 VXAA-1.1 - Drug Profile 166 WLBU-2 - Drug Profile 168 Z-3G1 - Drug Profile 169 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects 170 Influenza A Virus, H1N1 Subtype Infections - Discontinued Products 173 Influenza A Virus, H1N1 Subtype Infections - Product Development Milestones 174 Featured News & Press Releases 174 Appendix 186 Methodology 186 Coverage 186 Secondary Research 186 Primary Research 186 Expert Panel Validation 186 Contact Us 186 Disclaimer 187
List of Tables
Number of Products under Development for Influenza A Virus, H1N1 Subtype Infections, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by AbbVie Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Altimmune Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Antigen Express Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by CEL-SCI Corp, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cilian AG, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by ContraFect Corp, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Curevac AG, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by EpiVax Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Etubics Corp, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Genentech Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by iBio Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kineta Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Kyowa Hakko Kirin Co Ltd, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Medicago Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by MedImmune LLC, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Microbiotix Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Mucosis BV, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Novavax Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by PeptiDream Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Prommune Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Protein Sciences Corp, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Recce Ltd, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by TechnoVax Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Touchlight Genetics Ltd, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaccibody AS, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vaxart Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Vironova AB, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Visterra Inc, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2017 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..1), H1 2017 Influenza A Virus, H1N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..2), H1 2017 Influenza A Virus, H1N1 Subtype Infections - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
